This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krasnykh, V. Articles by Curiel, D. T. Search for Related Content PubMed PubMed Citation Articles by Krasnykh, V. Articles by Curiel, D. T.

Advanced Generation Adenoviral Vectors Possess Augmented Gene Transfer Efficiency Based upon Coxsackie Adenovirus Receptor-independent Cellular Entry Capacity¹

Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, and Gene Therapy Center, The University of Alabama at Birmingham, Birmingham, Alabama 35294-3300

Adenoviral (Ad) vectors have been widely used in the context of cancer gene therapy approaches. Their utility in these contexts, however, has frequently been limited by tumor cell resistance to Ad infection. The basis of this resistance has been defined recently as resulting from a deficiency of the primary adenovirus receptor, coxsackie adenovirus receptor. As a means to circumvent this limitation, a variety of tropism modification strategies have allowed coxsackie adenovirus receptor-independent gene delivery via the Ad vector. These advanced generation adenovirus vectors exhibit enhanced infectivity, which can allow direct therapeutic gain. Such vectors may allow improvements in efficacy in the context of ongoing human clinical gene therapy approaches for cancer.

This article has been cited by other articles:

				K. Matthews, P. E. Noker, B. Tian, S. D. Grimes, R. Fulton, K. Schweikart, R. Harris, R. Aurigemma, M. Wang, M. N. Barnes, et al. Identifying the Safety Profile of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Anticipation of a Phase I Clinical Trial in Patients with Recurrent Ovarian Cancer Clin. Cancer Res., June 15, 2009; 15(12): 4131 - 4137. [Abstract] [Full Text] [PDF]

				M. M. Alonso, M. Cascallo, C. Gomez-Manzano, H. Jiang, B. N. Bekele, A. Perez-Gimenez, F. F. Lang, Y. Piao, R. Alemany, and J. Fueyo ICOVIR-5 Shows E2F1 Addiction and Potent Antiglioma Effect In vivo Cancer Res., September 1, 2007; 67(17): 8255 - 8263. [Abstract] [Full Text] [PDF]

				M. Wakayama, M. Abei, R. Kawashima, E. Seo, K. Fukuda, H. Ugai, T. Murata, N. Tanaka, I. Hyodo, H. Hamada, et al. E1A, E1B Double-Restricted Adenovirus with RGD-Fiber Modification Exhibits Enhanced Oncolysis for CAR-Deficient Biliary Cancers Clin. Cancer Res., May 15, 2007; 13(10): 3043 - 3050. [Abstract] [Full Text] [PDF]

				Y. Tsuruta, L. Pereboeva, J. N. Glasgow, D. T. Rein, Y. Kawakami, R. D. Alvarez, R. P. Rocconi, G. P. Siegal, P. Dent, P. B. Fisher, et al. A Mosaic Fiber Adenovirus Serotype 5 Vector Containing Reovirus {sigma}1 and Adenovirus Serotype 3 Knob Fibers Increases Transduction in an Ovarian Cancer Ex vivo System via a Coxsackie and Adenovirus Receptor Independent Pathway Clin. Cancer Res., May 1, 2007; 13(9): 2777 - 2783. [Abstract] [Full Text] [PDF]

				J. Li, S. Lad, G. Yang, Y. Luo, M. Iacobelli-Martinez, F. J. Primus, R. A. Reisfeld, and E. Li Adenovirus Fiber Shaft Contains a Trimerization Element That Supports Peptide Fusion for Targeted Gene Delivery J. Virol., December 15, 2006; 80(24): 12324 - 12331. [Abstract] [Full Text] [PDF]

				A. Tamanini, E. Nicolis, A. Bonizzato, V. Bezzerri, P. Melotti, B. M. Assael, and G. Cabrini Interaction of Adenovirus Type 5 Fiber with the Coxsackievirus and Adenovirus Receptor Activates Inflammatory Response in Human Respiratory Cells J. Virol., November 15, 2006; 80(22): 11241 - 11254. [Abstract] [Full Text] [PDF]

				S. Komarova, Y. Kawakami, M. A. Stoff-Khalili, D. T. Curiel, and L. Pereboeva Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther., March 1, 2006; 5(3): 755 - 766. [Abstract] [Full Text] [PDF]

				M. A. Preuss, J. T. Lam, M. Wang, C. A. Leath III, M. Kataram, P. J. Mahasreshti, R. D. Alvarez, and D. T. Curiel Transcriptional Blocks Limit Adenoviral Replication in Primary Ovarian Tumor Clin. Cancer Res., May 1, 2004; 10(9): 3189 - 3194. [Abstract] [Full Text] [PDF]

				M. E. Goldsmith, M. Kitazono, P. Fok, T. Aikou, S. Bates, and T. Fojo The Histone Deacetylase Inhibitor FK228 Preferentially Enhances Adenovirus Transgene Expression in Malignant Cells Clin. Cancer Res., November 1, 2003; 9(14): 5394 - 5401. [Abstract] [Full Text] [PDF]

				T. Hakkarainen, A. Hemminki, A. V. Pereboev, S. D. Barker, C. K. Asiedu, T. V. Strong, A. Kanerva, J. Wahlfors, and D. T. Curiel CD40 Is Expressed on Ovarian Cancer Cells and Can Be Utilized for Targeting Adenoviruses Clin. Cancer Res., February 1, 2003; 9(2): 619 - 624. [Abstract] [Full Text] [PDF]

				Y. S. Haviv, J. L. Blackwell, A. Kanerva, P. Nagi, V. Krasnykh, I. Dmitriev, M. Wang, S. Naito, X. Lei, A. Hemminki, et al. Adenoviral Gene Therapy for Renal Cancer Requires Retargeting to Alternative Cellular Receptors Cancer Res., August 1, 2002; 62(15): 4273 - 4281. [Abstract] [Full Text] [PDF]

				E. A. Kashentseva, T. Seki, D. T. Curiel, and I. P. Dmitriev Adenovirus Targeting to c-erbB-2 Oncoprotein by Single-Chain Antibody Fused to Trimeric Form of Adenovirus Receptor Ectodomain Cancer Res., January 1, 2002; 62(2): 609 - 616. [Abstract] [Full Text] [PDF]

				A. Kanerva, G. V. Mikheeva, V. Krasnykh, C. J. Coolidge, J. T. Lam, P. J. Mahasreshti, S. D. Barker, M. Straughn, M. N. Barnes, R. D. Alvarez, et al. Targeting Adenovirus to the Serotype 3 Receptor Increases Gene Transfer Efficiency to Ovarian Cancer Cells Clin. Cancer Res., January 1, 2002; 8(1): 275 - 280. [Abstract] [Full Text] [PDF]

				M. Kitazono, M. E. Goldsmith, T. Aikou, S. Bates, and T. Fojo Enhanced Adenovirus Transgene Expression in Malignant Cells Treated with the Histone Deacetylase Inhibitor FR901228 Cancer Res., September 1, 2001; 61(17): 6328 - 6330. [Abstract] [Full Text] [PDF]